In the companion to this article, Dr Ruiz et al 5 conducted an analysis of two prospective studies using wearable accelerometer-based evaluations to define patients' fitness through a new score known ...
ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results